Extended oral anticoagulation after incident venous thromboembolism – a paradigm shift?

References

• Wendelboe AM, Raskob GE. Global burden of thrombosis: epidemiologic aspects. Circ Res. 2016;118(9):1340–1347.
   PubMed Web of Science ®Google Scholar
• Arshad N, Isaksen T, Hansen J-B, et al. Time trends in incidence rates of venous thromboembolism in a large cohort recruited from the general population. Eur J Epidemiol. 2017;32(4):299–305.
   PubMed Web of Science ®Google Scholar
• Münster AM, Rasmussen TB, Falstie-Jensen AM, et al. A changing landscape: temporal trends in incidence and characteristics of patients hospitalized with venous thromboembolism 2006–2015. Thromb Res. 2019;176:46–53.
   PubMed Web of Science ®Google Scholar
• Gustafsson N, Poulsen PB, Stallknecht SE, et al. Societal costs of venous thromboembolism and subsequent major bleeding events: a national register-based study. Eur Hear journal Qual care Clin outcomes. 2019July. DOI:10.1093/ehjqcco/qcz035
   Web of Science ®Google Scholar
• Piazza G, Goldhaber SZ. Chronic thromboembolic pulmonary hypertension. N Engl J Med. 2011;364(4):351–360.
   PubMed Web of Science ®Google Scholar
• Galanaud J-P, Monreal M, Kahn SR. Epidemiology of the post-thrombotic syndrome. Thromb Res. 2018;164:100–109.
   PubMed Web of Science ®Google Scholar
• Søgaard KK, Schmidt M, Pedersen L, et al. 30-Year mortality after venous thromboembolism a population-based cohort study. Circulation. 2014;130(10):829–836.
   PubMed Web of Science ®Google Scholar
• Larsen TB, Lip GYH, Gorst-Rasmussen A. Anticoagulant therapy after venous thromboembolism and 10-year mortality. Int J Cardiol. 2016;208:72–78.
   PubMed Web of Science ®Google Scholar
• Prandoni P, Noventa F, Ghirarduzzi A, et al. The risk of recurrent venous thromboembolism after discontinuing anticoagulation in patients with acute proximal deep vein thrombosis or pulmonary embolism. A prospective cohort study in 1,626 patients. Haematologica. 2007;92(2):199–205.
   PubMed Web of Science ®Google Scholar
• Albertsen IE, Nielsen PB, Søgaard M, et al. Venous thromboembolism and risk of recurrence: a Danish nationwide cohort study. Am J Med. 2018;131(9):1067–1074.
   PubMed Web of Science ®Google Scholar
• Khan F, Rahman A, Carrier M, et al. Long term risk of symptomatic recurrent venous thromboembolism after discontinuation of anticoagulant treatment for first unprovoked venous thromboembolism event: systematic review and meta-analysis. BMJ. 2019;366:l4363.
   PubMed Web of Science ®Google Scholar
• Ensor J, Riley RD, Moore D, et al. Systematic review of prognostic models for recurrent venous thromboembolism (VTE) post-treatment of first unprovoked VTE. BMJ Open. 2016;6(5):e011190.
   PubMed Web of Science ®Google Scholar
• Kahn SR, Lim W, Dunn AS, et al. Prevention of VTE in nonsurgical patients: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest. 2012;141(2):e195S–e226S.
   PubMed Web of Science ®Google Scholar
• Mazzolai L, Aboyans V, Ageno W, et al. Diagnosis and management of acute deep vein thrombosis: a joint consensus document from the European Society of Cardiology working groups of aorta and peripheral circulation and pulmonary circulation and right ventricular function. Eur Heart J. 2017 February;1–13. DOI:10.1093/eurheartj/ehx003
   PubMedGoogle Scholar
• Couturaud F, Sanchez O, Pernod G, et al. Six months vs extended oral anticoagulation after a first episode of pulmonary embolism. Jama. 2015;314(1):31.
   PubMed Web of Science ®Google Scholar
• Martinez C, Cohen AT, Bamber L, et al. Epidemiology of first and recurrent venous thromboembolism: A population-based cohort study in patients without active cancer. Thromb Haemost. 2014;112(2):255–263.
   PubMed Web of Science ®Google Scholar
• Martinez C, Katholing A, Folkerts K, et al. Risk of recurrent venous thromboembolism after discontinuation of vitamin K antagonist treatment: a nested case-control study. J Thromb Haemost. 2016;14(7):1374–1383.
   PubMed Web of Science ®Google Scholar
• Middeldorp S, Prins MH, Hutten BA. Duration of treatment with vitamin K antagonists in symptomatic venous thromboembolism. Cochrane Database Syst Rev. 2014;2014(8):CD001367.
   Google Scholar
• Streiff MB, Holmstrom B, Angelini D, et al. NCCN guidelines insights: cancer-associated venous thromboembolic disease, version 2.2018. J Natl Compr Canc Netw. 2018;16(11):1289–1303.
   PubMed Web of Science ®Google Scholar
• Piran S, Schulman S. Management of recurrent venous thromboembolism in patients with cancer: A review. Thromb Res. 2018;164:S172–S177.
   PubMed Web of Science ®Google Scholar
• Konstantinides SV, Meyer G, Becattini C, et al. ESC Guidelines for the diagnosis and management of acute pulmonary embolism developed in collaboration with the European Respiratory Society (ERS). Eur Heart J. 2019;(August):2019. DOI:10.1093/eurheartj/ehz405
   Google Scholar
• Kearon C, Akl EA, Ornelas J, et al. Antithrombotic therapy for VTE disease. CHEST guideline and expert panel report. Chest. 2016;149(2):315–352.
   PubMed Web of Science ®Google Scholar
• Kearon C, Ginsberg JS, Kovacs MJ, et al. Comparison of low-intensity warfarin therapy with conventional-intensity warfarin therapy for long-term prevention of recurrent venous thromboembolism. N Engl J Med. 2003;349(7):631–639.
   PubMed Web of Science ®Google Scholar
• Ridker PM, Goldhaber SZ, Danielson E, et al. Long-term, low-intensity warfarin therapy for the prevention of recurrent venous thromboembolism. N Engl J Med. 2003;348(15):1425–1434.
   PubMed Web of Science ®Google Scholar
• Schulman S, Rhedin A-S, Lindmarker P, et al. A comparison of six weeks with six months of oral anticoagulant therapy after a first episode of venous thromboembolism. N Engl J Med. 1995;332(25):1661–1665.
   PubMed Web of Science ®Google Scholar
• Schulman S, Kearon C, Kakkar AK, et al. Extended use of dabigatran, warfarin, or placebo in venous thromboembolism. N Engl J Med. 2013;368(8):709–718.
   PubMed Web of Science ®Google Scholar
• Bauersachs R, Berkowitz SD, Brenner B, et al. Oral rivaroxaban for symptomatic venous thromboembolism. N Engl J Med. 2010;363(26):2499–2510.
   PubMed Web of Science ®Google Scholar
• Weitz JI, Lensing AWA, Prins MH, et al. Rivaroxaban or aspirin for extended treatment of venous thromboembolism. N Engl J Med. 2017;376(13):1211–1222.
   PubMed Web of Science ®Google Scholar
• Agnelli G, Buller HR, Cohen A, et al. Apixaban for extended treatment of venous thromboembolism. N Engl J Med. 2013;368(8):699–708.
   PubMed Web of Science ®Google Scholar
• Raskob G, Ageno W, Cohen AT, et al. Extended duration of anticoagulation with edoxaban in patients with venous thromboembolism: a post-hoc analysis of the Hokusai-VTE study. Lancet Haematol. 2016;3(5):e228–36.
   PubMed Web of Science ®Google Scholar
• Andreozzi GM, Bignamini AA, Davì G, et al. Sulodexide for the prevention of recurrent venous thromboembolism: the sulodexide in Secondary Prevention of Recurrent Deep Vein Thrombosis (SURVET) study: a multicenter, randomized, double-blind, placebo-controlled trial. Circulation. 2015;132(20):1891–1897.
   PubMed Web of Science ®Google Scholar
• Brighton TA, Eikelboom JW, Mann K, et al. Low-dose aspirin for preventing recurrent venous thromboembolism. N Engl J Med. 2012;367(21):1979–1987.
   PubMed Web of Science ®Google Scholar
• Becattini C, Agnelli G, Schenone A, et al. Aspirin for preventing the recurrence of venous thromboembolism. N Engl J Med. 2012;366(21):1959–1967.
   PubMed Web of Science ®Google Scholar
• Albertsen IE, Piazza G, Goldhaber SZ. Let’s stop dichotomizing venous thromboembolism as provoked or unprovoked. Circulation. 2018;138(23):2591–2593.
   PubMed Web of Science ®Google Scholar
• Albertsen IE, Søgaard M, Goldhaber SZ, et al. Development of sex-stratified prediction models for recurrent venous thromboembolism: a Danish nationwide cohort study. Thromb Haemost. 2020. DOI:10.1055/s-0040-1708877.
   PubMed Web of Science ®Google Scholar
• Timp JF, Braekkan SK, Lijfering WM, et al. Prediction of recurrent venous thrombosis in all patients with a first venous thrombotic event: the Leiden Thrombosis Recurrence Risk Prediction model (L-TRRiP). PLoS Med. 2019;16(10):e1002883.
   PubMed Web of Science ®Google Scholar
• Rodger MA, Kahn SR, Wells PS, et al. Identifying unprovoked thromboembolism patients at low risk for recurrence who can discontinue anticoagulant therapy. CMAJ. 2008;179(5):417–426.
   PubMed Web of Science ®Google Scholar
• Tosetto A, Iorio A, Marcucci M, et al. Predicting disease recurrence in patients with previous unprovoked venous thromboembolism: A proposed prediction score (DASH). J Thromb Haemost. 2012;10(6):1019–1025.
   PubMed Web of Science ®Google Scholar
• Kearon C, Iorio A, Palareti G. Risk of recurrent venous thromboembolism after stopping treatment in cohort studies: recommendation for acceptable rates and standardized reporting. J Thromb Haemost. 2010;8(10):2313–2315.
   PubMed Web of Science ®Google Scholar
• van Es N, Coppens M, Schulman S, et al. Direct oral anticoagulants compared with vitamin K antagonists for acute venous thromboembolism: evidence from phase 3 trials. Blood. 2014;124(12):1968–1975.
   PubMed Web of Science ®Google Scholar
• Beyer-Westendorf J, Förster K, Pannach S, et al. Rates, management, and outcome of rivaroxaban bleeding in daily care: results from the Dresden NOAC registry. Blood. 2014;124(6):955–962.
   PubMed Web of Science ®Google Scholar
• Palareti G, Cosmi B, Legnani C, et al. D-dimer testing to determine the duration of anticoagulation therapy. N Engl J Med. 2006;355(17):1780–1789.
   PubMed Web of Science ®Google Scholar
• Douketis J, Tosetto A, Marcucci M, et al. Patient-level meta-analysis: effect of measurement timing, threshold, and patient age on ability of D-dimer testing to assess recurrence risk after unprovoked venous thromboembolism. Ann Intern Med. 2010;153(8):523–531.
   PubMed Web of Science ®Google Scholar
• Palareti G, Cosmi B, Legnani C, et al. D-dimer to guide the duration of anticoagulation in patients with venous thromboembolism: a management study. Blood. 2014;124(2):196–203.
   PubMed Web of Science ®Google Scholar
• Eichinger S, Heinze G, Jandeck LM, et al. Risk assessment of recurrence in patients with unprovoked deep vein thrombosis or pulmonary embolism: the Vienna prediction model. Circulation. 2010;121(14):1630–1636.
   PubMed Web of Science ®Google Scholar
• Franco Moreno AI, García Navarro MJ, Ortiz Sánchez J, et al. A risk score for prediction of recurrence in patients with unprovoked venous thromboembolism (DAMOVES). Eur J Intern Med. 2016;29:59–64.
   PubMed Web of Science ®Google Scholar
• Eichinger S, Weltermann A, Minar E, et al. Symptomatic pulmonary embolism and the risk of recurrent venous thromboembolism. Arch Intern Med. 2004;164(1):92–96.
   PubMedGoogle Scholar
• Tritschler T, Castellucci LA. It’s time for head-to-head trials with direct oral anticoagulants. Thromb Res. 2019;180:64–69.
   PubMed Web of Science ®Google Scholar
• Castellucci LA, de Wit K, Garcia D, et al. Extended anticoagulation for unprovoked venous thromboembolism. Res Pract Thromb Haemost. 2018;2(3):529–534.
   PubMed Web of Science ®Google Scholar
• Albertsen IE, Goldhaber SZ, Piazza G, et al. Predictors of not initiating anticoagulation after incident venous thromboembolism: a Danish nationwide cohort study. Am J Med. 2019. DOI:10.1016/j.amjmed.2019.08.051.
   PubMed Web of Science ®Google Scholar
• Schulman S, Ageno W, Konstantinides SV. Venous thromboembolism: past, present and future. Thromb Haemost. 2017;117(7):1219–1229.
   PubMed Web of Science ®Google Scholar